Pulmonary Hypertension | Treatment Algorithms: Claims Data Analysis | US | 2020
Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder marked by considerable morbidity and mortality. A wide array of drugs are available to treat PAH. Phosphodiesterase 5 (PDE-5) inhibitors and endothelin receptor antagonists (ERAs) are the most commonly prescribed first-line treatments; the more-efficacious prostacyclin therapies are used in later lines. Branded therapies dominate the PAH treatment algorithm, and combination therapy is common.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed PAH patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed PAH patients?
- How have Uptravi, Orenitram, Remodulin, and Adempas been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of PAH patients receive drug therapy within two years of diagnosis and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
- What percentage of PAH patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
KEY DRUGS COVERED
- Adcirca, Tracleer, Letairis, Opsumit, Tyvaso, Ventavis, Orenitram, Uptravi, Remodulin, Adempas, sildenafil, epoprostenol
Related Market Assessment Reports
Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder affecting hair follicles. It is characterized by the occurrence of inflamed and swollen lesions, which are typically…
Report
Immunoglobulin A Nephropathy – Access & Reimbursement – Access & Reimbursement – Immunoglobulin A Nephropathy (US)
The U.S. IgA nephropathy (IgAN) therapy market predominantly comprises supportive treatments such as RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance…
Report
Axial Spondyloarthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Ankylosing Spondylitis (US)
Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the sacroiliac joints and the axial skeleton, leading to persistent back pain and stiffness. The main treatment…
